Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 15/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787853 | 0.87 | EPHX2 (0.67) | SMN1; SMN2EPHX2CYP2C9GAAHTT | |
| SCHEMBL3473829 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2EPHX2CYP2C9GAAHTT | |
| SCHEMBL3474830 | 0.84 | EPHX2 (0.55) | SMN1; SMN2EPHX2CYP2C9GAAHTT | |
| SCHEMBL3471782 | 0.83 | EPHX2 (0.79) | EPHX2CYP2C9 | |
| SCHEMBL3472485 | 0.82 | POLB (0.55) | SMN1; SMN2EPHX2CYP2C9GAAHTT | |
| SCHEMBL2786704 | 0.79 | EPHX2 (0.66) | EPHX2CYP2C9GAAHTTP2RX7 | |
| SCHEMBL2261513 | 0.79 | EPHX2 (0.66) | SMN1; SMN2EPHX2CYP2C9GAAHTT | |
| SCHEMBL2786343 | 0.78 | EPHX2 (0.57) | SMN1; SMN2EPHX2CYP2C9GAAHTT | |
| SCHEMBL2265564 | 0.77 | EPHX2 (0.57) | SMN1; SMN2EPHX2CYP2C9KDM4EP2RX7 | |
| SCHEMBL2677652 | 0.77 | EPHX2 (0.55) | SMN1; SMN2EPHX2CYP2C9GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | claimed |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| WO-2009097474-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | SMN1; SMN2 4459/4885EPHX2 5/4885CYP2C9 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.